Muhammad Taqi, MD
Vascular Neurology · Palm Springs, CANPI 1013123280
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Rapid Medical Ltd accounts for 66.0% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2019 at $46,256 and has fallen 95.8% since, to $1,924 in 2025. Among vascular neurology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 257 payments — averaging $299.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rapid Medical Ltd$51K
- Stryker$6K
- Penumbra, Inc.$5K
- Medtronic$5K
- Balt USA, LLC$4K
- Silk Road Medical, Inc.$1K
- plus $6K from 34 others
Across 131 payments — averaging $3938.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medical Device Business Services, Inc.$212K
- Balt USA, LLC$147K
- Penumbra, Inc.$49K
- Stryker$44K
- Rapid Medical Ltd$37K
- MIVI Neuroscience, Inc.$18K
- plus $7K from 1 others
What the payments were for
- Consulting fees$13,20017%
- Speaking & faculty fees$30,95040%
- Travel & lodging$16,08121%
- Food & beverage$16,78222%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rapid Medical Ltd | 16 | $50,879 |
| Stryker | 45 | $5,937 |
| Penumbra, Inc. | 18 | $4,726 |
| Medtronic(2 entities) | 28 | $4,640 |
| Balt USA, LLC | 18 | $3,882 |
| Silk Road Medical, Inc. | 11 | $1,211 |
| Edwards Lifesciences | 8 | $729 |
| AbbVie(2 entities) | 29 | $642 |
| Johnson & Johnson(2 entities) | 16 | $564 |
| Qapel Medical Inc | 2 | $450 |
| Siemens Medical Solutions USA, Inc. | 4 | $421 |
| Scientia Vascular | 4 | $409 |
| Abbott | 6 | $346 |
| Viz.ai, Inc. | 5 | $297 |
| Phenox Inc. | 3 | $204 |
| Route 92 Medical, Inc. | 1 | $183 |
| Inspiremd Ltd | 1 | $178 |
| Imperative Care, Inc | 2 | $161 |
| AstraZeneca | 7 | $160 |
| Boston Scientific | 1 | $150 |
| Amgen | 5 | $128 |
| Xtant Medical Inc | 1 | $121 |
| Merz Pharmaceuticals, LLC | 2 | $74 |
| Saluda Medical Americas, Inc. | 1 | $63 |
| Microtransponder, Inc. | 2 | $58 |
| Lilly USA, LLC | 2 | $52 |
| Angiodynamics, Inc. | 3 | $52 |
| Cardiva Medical, Inc. | 2 | $45 |
| Grifols USA, LLC | 2 | $44 |
| UCB, Inc. | 1 | $36 |
| Microvention, Inc. | 1 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $27 |
| Neurelis, Inc. | 1 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $25 |
| Impel Pharmaceuticals Inc. | 1 | $24 |
| Portola Pharmaceuticals, LLC | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Merz North America, Inc. | 1 | $17 |
| SK Life Science, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Comaneci$38,764
- COMANECI 17$11,833
- TIGERTRIEVER 17 REVASCULARIZATION DEVICE$11,833
- TREVO$2,763
- Penumbra SMART Coil$2,400
- Pipeline$2,363
- Optima Thermal Coil System$2,331
- Penumbra System$1,624
- WINGSPAN$1,279
- SURPASS EVOLVE$1,226
- ENROUTE Transcarotid Neuroprotection System$1,069
- ENROUTE Transcarotid Stent System$1,069
- ENHANCE Transcarotid Peripheral Access Kit$1,069
- ENROUTE 0.014 Guidewire$1,069
- SOLITAIRE X$982
- SURPASS$638
- Penumbra Coil 400$517
- TARGET$485
- Solitaire$472
- HemoSphere$395
How this compares
$77,071 in reported general payments places this provider in the 90th percentile of 58 vascular neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 86 | $65,331 |
| XareltoRivaroxaban | 33 | $24,437 |
| BrilintaTicagrelor | 29 | $16,448 |
| Emgality PenGalcanezumab-Gnlm | 11 | $7,341 |
| ClopidogrelClopidogrel Bisulfate | 200 | $2,145 |
| Memantine Hcl ErMemantine Hcl | 22 | $1,891 |
| Levetiracetam | 54 | $1,669 |
| Propranolol Hcl ErPropranolol Hcl | 25 | $943 |
| Memantine Hcl | 26 | $787 |
| Donepezil Hcl | 106 | $780 |
| Oxcarbazepine | 11 | $687 |
| Nortriptyline Hcl | 66 | $655 |
| Atorvastatin Calcium | 64 | $445 |
| Primidone | 30 | $432 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 15 | $336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $564 | $24,43733 claims |
| AstraZenecaBrilinta | $160 | $16,44829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 58 vascular neurology providers in California.
Other vascular neurology in Palm Springs
- Gregory AlbersStanford$415K
- Chitra VenkatasubramanianStanford$260K
- Shuichi SuzukiArcadia$126K
- Royya ModirSan Diego$113K
- Maarten LansbergStanford$86K
- Ashish NandaFullerton$66K
- Andrew XavierMountain View$46K
- Sarah LeeStanford$35K
- May NourLos Angeles$32K
- Banafsheh YafehLong Beach$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.